Today, Great Bay Bio (GBB) announced an expanded strategic partnership with Chime Biologics, a global leader in CDMO. This deepened collaboration will integrate GBB’s advanced AI-enabled drug development ecosystem with Chime Biologics' outstanding CDMO services, using cutting-edge technologies such as AI to jointly accelerate the development of biopharmaceuticals for global clients.

According to the agreement, Great Bay Bio will leverage its extensive expertise in AI, big data mining, and automation, particularly its unique advantages in cell line development, to provide comprehensive support for early drug discovery and subsequent bioprocess development. The two companies will combine GBB’s AlfaCell, the world’s first commercial site-specific integration cell line development platform, with Chime Biologics’ excellent CDMO capabilities to deliver faster, higher-quality, and more intelligent solutions to help global clients obtain stable, high-expression cell lines and accelerate the clinical trial and commercialization processes.

Great Bay Bio and Chime Biologics first disclosed their strategic partnership in 2021, focusing on the Greater China region.

Dr. Michael Chen, Co-Founder and CEO of Great Bay Bio, commented, "We are excited to deepen our collaboration with Chime Biologics. Chime Biologics brings comprehensive biomanufacturing capabilities and internationally recognized expertise, offering high-quality preclinical research, clinical trials, and commercial manufacturing services to clients worldwide. This perfectly aligns with Great Bay Bio’s innovative capabilities and accelerates the global commercialization of our intelligent technology platforms, making global bioprocessing simpler and more efficient."

Dr. Jimmy Wei, President of Chime Biologics, commented, "The deepened strategic cooperation between Chime Biologics and Great Bay Bio is an excellent match with our shared vision. By integrating GBB’s intelligent drug development ecosystem with Chime’s integrated CDMO services and technological platform, we will complement each other’s strengths and explore new models and pathways for biopharmaceutical development. Together, we aim to provide more efficient and high-quality biopharmaceutical development services to global clients, ultimately benefiting patients and improving global health."

About Great Bay Bio

Great Bay Bio (GBB), headquartered in HKSTP, is a biotech company that drives drug development using cutting-edge technologies such as AI, big data mining, and automation. GBB adheres to the corporate vision of "Global Bioprocessing Made Simpler and More Efficient," and aims to address the challenges of long timelines, high costs, and low success rates in drug development, with a long-term goal of enhancing human life, health, and value. To learn more, visit: www.greatbay-bio.com.cn.

About Chime Biologics

Chime Biologics is a global leading CDMO that has introduced the first modular biopharmaceutical plant KUBio™ in the world to empower its partners’ success in biologics in the whole process from cell line development to commercial manufacturing. Relying on cell line development and advanced technology development from our Shanghai Innovation Center and proven success in IND-enabling through market registration at its Wuhan plant, Chime Biologics is providing a one-stop CMC solution for biopharmaceutical customers around the world. We share a common goal to make cutting-edge biomedicines affordable and accessible to all patients globally, fulfilling its commitment to human health. For more information, please visit: www.chimebiologics.com.